secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001558370-22-016231
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium Q3 record revenue $127M (+61% YoY), adj. EPS $1.10, raises FY guidance; completes Xtampza ER renegotiation
--------------------------------------------------------------------------------

- Record Q3 revenue $127.0M (+61% YoY); GAAP net income $0.5M ($0.01 EPS), adj. net income $42.5M ($1.10 adj. EPS).
- Completed Xtampza ER contract renegotiations; gross-to-net <65% effective Jan 1, 2023, maintaining broad access.
- Returned $10M capital via share repurchases ($6.4M in Q3, $3.6M in Oct). $42.1M remains under $100M program.
- Updated FY2022 guidance: revenue $455-465M, adj. EBITDA $250-255M, adj. opex $125-130M.
- Ended Q3 with $134.1M cash; made $25M debt repayments; BDSI synergy target raised to ~$85M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000155837022016231/0001558370-22-016231-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000155837022016231/coll-20221103x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-016231

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer